Potential of the 8-CLR signature in immunotherapy and chemotherapy
cancer, RS, tumour, IPS
CANCER, TUMOUR, SOMATIC MUTATIONS
Immunotherapies have shown promising outstanding therapeutic effects in multiple types of malignant solid tumoursThe TMB is the total number of somatic mutations in each coding region of the tumour cell genome. The TMB between the different risk subgroups is shown in Fig. Analysis of TMB and immune checkpoints molecules. (Immune checkpoint inhibitors (ICIs), important agents in tumour immunotherapy with prominent clinical benefits, are transforming cancer treatment in every aspectThe immunophenoscore (IPS) of CTLA-4 and PD-1 inhibitors in 307 CC patients was retrieved from the TCIA database; samples with missing data were eliminated, with 304 samples for subsequent analysis. The results showed that the low-risk group responded better to immunotherapy when treated with either a PD-1 inhibitor alone or a CTLA-4 inhibitor in combination with a PD-1 inhibitor, while there was no statistically significant difference in response to immunotherapy without PD-1 inhibitors between the two groups (Fig. Response to immunotherapy and chemotherapy. (Finally, we used the “pRRophetic” R package to assess the value of our prediction model for guiding the clinical use of chemotherapeutic agents in patients with CC by comparing IC50 data for some commonly used chemotherapeutic agents between risk subgroups. Several anticancer drugs showed significantly different IC50 values between the two risk subgroups. Moreover, based on the 8-CRLs signature, the low-risk CC patients were more susceptible to A-443654, DMOG, GSK690693, navitoclax, temozolomide, and ZSTK474, which may be more appropriate for patients with a lower RS (Fig. 